- Home
- SA vs DNLI Comparison
SA vs DNLI Comparison
Compare SA & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SA | DNLI |
|---|---|---|
| Founded | 1979 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 2004 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SA | DNLI |
|---|---|---|
| Price | $24.37 | $24.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $65.00 | $34.33 |
| AVG Volume (30 Days) | 1.0M | ★ 1.8M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $408.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.00 | $12.58 |
| 52 Week High | $40.06 | $25.31 |
Technical Indicators
Market Signals| Indicator | SA | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 36.32 | 74.12 |
| Support Level | $23.00 | $18.27 |
| Resistance Level | $32.13 | N/A |
| Average True Range (ATR) | 2.39 | 1.24 |
| MACD | -0.44 | 0.44 |
| Stochastic Oscillator | 4.56 | 88.15 |
Price Performance
Historical ComparisonAbout SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development stage company involved in the exploration and development of gold properties situated in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, the Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.